Summit Therapeutics (SMMT) is down -24.1%, or -$6.27 to $19.71.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- EchoStar sells spectrum licenses to SpaceX, StubHub to launch IPO: Morning Buzz
- Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX
- Summit Therapeutics Reveals Promising Phase III Trial Results
- Summit Therapeutics’ Ivonescimab: Promising Efficacy and Market Potential Reinforce Buy Rating
- Positive Buy Rating for Summit Therapeutics Driven by Promising HARMONi Trial Results and Anticipated Stock Upside